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Abstract 
Insulin-like growth factor-I (IGF-I) has growth promoting effects as well as insulin-like 
actions on metabolism. IGF-I associates with a family of six high affinity IGF-binding 
proteins (IGFBPs) and these interfere in immunoassays for IGF-I. The role of binding 
of IGF-I to IGFBP-3, together with a third protein (the acid-labile subunit), to form a 
high molecular mass ternary complex, is not known in cats. In adult humans the ternary 
complex is the dominant circulating form. The cat is a strict carnivore with different 
metabolism to other species, which may include differences in the IGF system. In 
clinical practice serum IGF-I is used routinely for screening for acromegaly in cats with 
diabetes mellitus (DM). The overall aim of this thesis was to determine factors 
regulating IGF-I concentrations in health and disease. 
Enzyme-linked immunosorbent assays for measuring feline IGF-I and insulin were 
validated. It is recommended that laboratories, in validating their assays, should be 
aware of position effects on assay plates and, for IGF-I assays, interference by 
circulating IGFBPs. For IGF-I, between animal variation was high (~65%) while within 
animal variation was considerable lower (~8%). These values for biological variation 
can now be used in interpreting clinical results after repeated sampling in screening for, 
and in the management of, acromegaly. 
IGF-I concentrations were related to the amount of the ternary complex in healthy 
and diabetic cats. The ternary complex was the dominating circulating form only in cats 
with high IGF-I concentrations. There was a wide range of IGF-I concentrations in both 
healthy and diabetic cats that was in part related to variation in weight.  
When using IGF-I as a screening tool for acromegaly in diabetic cats, glycaemic 
control should also be taken into consideration. IGF-I concentrations increased in 
response to insulin treatment and concentrations at 2-4 weeks were higher in cats that 
later went into remission. 
In conclusion, in contrast to adult humans, circulating IGF-binding forms vary across 
the wide range of IGF-I concentrations in the cat. It is recommended that reference 
intervals for healthy cats are developed, stratifying by weight. IGF-I shows promise as 
a predictive marker for remission in feline diabetes mellitus. 
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1 IGF system 
1.1 IGF physiology 
Insulin-like growth factors (IGFs) are important for growth and metabolism. In 
mammals there are two IGFs, IGF-I and IGF-II, which are structurally similar 
to insulin with overlapping effects through their structurally similar receptors 
(Clemmons, 2012; Bonefeld & Moller, 2011). In contrast to insulin, which is 
secreted by pancreatic beta cells, IGFs are expressed ubiquitously with 
production by the liver being the major source to the circulation (Daughaday & 
Rotwein, 1989). IGF-I in humans is a 7.6 kDa protein (Rinderknecht & 
Humbel, 1978) and cats have identical amino acid sequence (Sundberg, 2015). 
Insulin-like growth factors bind to a family of high-affinity insulin-like growth 
factor binding proteins (IGFBP-1to IGFBP-6) which modulate the function of 
IGFs and also have IGF-independent roles (Firth & Baxter, 2002). In healthy 
adult humans almost all IGFs circulate in a ternary complex form comprising 
IGFBP-3 or IGFBP-5 and a third protein of ~85kDa, the acid-labile subunit 
(ALS) (Baxter, 2001b). IGFs and IGFBP-3 or IGFBP-5 form a binary complex 
before associating with ALS (Baxter et al., 1989). Binary complexes of IGFs 
and IGFBP-3 bind to ALS with twice the affinity of IGF-IGFBP-5 complexes 
(Twigg & Baxter, 1998). In healthy adult humans ALS circulates in excess of 
the ternary complex and is therefore considered not to be rate limiting for 
ternary complex formation (Baxter, 1988). While binary complexes, (~30-50 
kDa) and free IGFs can pass the endothelial barrier, the ternary complex 
(~150kDa) cannot exit the circulation and this form is considered a storage 
pool that prolongs the half-life of IGFs (Boisclair et al., 2001). GH is secreted 
from the anterior pituitary gland in a pulsatile pattern and stimulates hepatic 
synthesis of ALS and IGF-I and thus is a regulator of the ternary complex 
(Olivecrona et al., 1999). The GH-dependence of IGFBP-3 and IGF-II is 
mainly due to binding in the ternary complex, so that their circulating half-lives 
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are prolonged (Olivecrona et al., 1999). In humans IGF-II circulates in 3:1 
molar ratio of IGF-I (Livingstone & Borai, 2014).  
The physiology of the IGF system has not been well characterized in cats 
but one study found that in healthy cats ALS did not circulate in excess of the 
ternary complex (Lewitt et al., 2000). In contrast to healthy cats, diabetic cats 
in that study seemed to have excess ALS and higher IGF-I concentrations. In 
support of this finding another report demonstrated that diabetic cats had 
higher IGF-I concentrations than healthy cats (Starkey et al., 2004). Other 
studies however documented low IGF-I concentrations in newly diagnosed 
diabetic cats which normalized during treatment (Alt et al., 2007; Reusch et 
al., 2006). The reasons for these discrepancies are not known but it was 
suggested that differences in methodology or treatment status could be 
contributing factors (Tschuor et al., 2012; Reusch et al., 2006). 
1.2 Predictors of IGF-I concentrations in cats 
There are few studies on the regulation of the IGF system in healthy cats. 
There is a correlation between GH and IGF-I in acromegalic cats (Niessen et 
al., 2007) and pituitary GH is considered to be a stimulator of IGF-I synthesis. 
In one study 14 days of caloric restriction was reported to decrease IGF-I 
concentrations, but IGF-II immunoreactivity and total IGFBP-3 visualized by 
Western ligand blotting (WLB) did not seem to change (Maxwell et al., 1999). 
In that study, in contrast to studies in humans (Baxter, 2001a) IGFBP-1 
identified by WLB was not increased by short term fasting (18h)(Maxwell et 
al., 1999). 
In two studies of newly diagnosed diabetic cats IGF-I concentrations 
increased to similar values as the control group during insulin treatment and it 
was considered likely that this related to improved nutritional status (Alt et al., 
2007; Reusch et al., 2006). However, in one study, IGF-I concentrations did 
not vary between well-controlled and poorly-controlled diabetic cats (Berg et 
al., 2007). 
Weight has been reported to have a positive association with IGF-I 
concentrations in healthy and diabetic cats (Niessen et al., 2015; Berg et al., 
2007; Maxwell et al., 1999) however one study did not find any association 
(Reusch et al., 2006).  
Age and gender are often used for stratifying reference intervals for IGF-I 
in humans. In one study of healthy cats age and IGF-I concentrations were not 
associated (Maxwell et al., 1999) whereas another study of healthy cats found 
a weak negative correlation, and no effect of sex (Reusch et al., 2006). In one 
study male cats had higher IGF-I concentrations but this was considered 
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dependent on male cats being heavier (Maxwell et al., 1999). Most studies do 
not adjust for any effect of castration. 
1.3 Measurements of GH, IGFs, and IGFBPs in feline medicine 
GH is produced in a pulsatile pattern which may cause difficulties if 
interpreting one single measurement. Nevertheless, in studies of cats, single 
measurements have proven useful for diagnosis of acromegaly and may aid in 
diagnosis (Niessen et al., 2007). However commercial laboratories do not 
routinely offer feline GH analyses. Instead GH-related diseases are diagnosed 
by measuring IGF-I, which is provided by a few specialist veterinary 
laboratories. Circulating IGF-I concentrations are stable during multiple 
sampling over the course of 12h (Reusch et al., 2006). In feline medicine the 
most common application for IGF-I analysis is in screening for acromegaly, 
which is almost exclusively diagnosed in insulin resistant diabetic cats (Hurty 
& Flatland, 2005). Dwarfism due to lack of pituitary GH has been reported in a 
cat with proportional dwarfism (Donaldson et al., 2008) but the syndrome is 
extremely rare or underdiagnosed in cats 
There is a notable paucity of literature in relation to non-islet cell tumour 
hypoglycaemia in cats and the use of IGF-II measurement in this setting has 
not yet been investigated. IGF-II and IGFBP-assays are at present not available 
in feline medicine. 
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2 Feline diabetes mellitus and acromegaly 
2.1 Diabetes mellitus 
Prevalence of feline diabetes mellitus (DM) in animal hospitals is increasing 
and part of this increase is thought to be due to lifestyle changes with obesity 
as a consequence (Rieder et al., 2008; Prahl et al., 2007). It is estimated that 
obesity in cats increases the risk of developing DM by threefold (Scarlett & 
Donoghue, 1998).  
In humans DM can be classified into type 1 or 2 DM according to the 
patterns of clinical characteristics, endogenous insulin secretion and islet-cell 
and insulin autoantibodies. Type 2 DM is typically characterized by insulin 
resistance and beta cell dysfunction and insulin concentrations may be high, 
normal or low (Saisho, 2015; Vague & Nguyen, 2002). Type 1 DM is typically 
characterized by insulin deficiency (ADA, 2004). Most cats present with a 
form of DM which resembles human type 2 (Nelson & Reusch, 2014), 
however insulin concentrations are usually lower than in healthy cats (Nelson 
et al., 1999; Lutz & Rand, 1996; Kirk et al., 1993). One hypothesis for the low 
insulin concentrations in cats with type 2 DM is beta cell impairment due to 
glucotoxicity (Zini et al., 2009), which can be reversible with adequate 
treatment (Tschuor et al., 2011; Nelson et al., 1999). The statement that cats 
mainly present with type 2 DM is based on the presence of amyloid in the 
pancreas, lack of antibodies against beta cells and lack of lymphocytic 
infiltration of beta cells (Hoenig, 2002). The classification of type 1 or type 2 is 
at present not considered clinically relevant because it is recommended that all 
cats presenting with clinical DM are treated with insulin (Rucinsky et al., 
2010). Furthermore insulin concentrations at diagnosis of DM do not predict 
whether a cat goes into remission (Tschuor et al., 2011; Nelson et al., 1999). A 
remission rate, defined by insulin independence, of 14-78% has been reported 
for cats with DM (Hafner et al., 2014; Nack & DeClue, 2014; Hall et al., 2009; 
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Michiels et al., 2008; Alt et al., 2007) and depends on achieving early 
glycaemic control (Gottlieb & Rand, 2013). 
2.1.1 Diagnosis 
Diagnosis of feline DM is based on hyperglycaemia and glycosuria together 
with clinical signs, such as polyuria/polydipsia, weight loss and polyphagia 
(Sparkes et al., 2015). The renal threshold for glycosuria in cats is about 15 
mmol/L and thus diagnosis of feline DM is usually made when cats present 
with profound hyperglycaemia. The use of hyperglycaemia alone as a 
diagnostic tool for DM in cats is complicated by the phenomena of stress 
hyperglycaemia and elevated serum glucose concentrations cannot solely be 
used for diagnosing DM in cats (Laluha et al., 2004).  
Fructosamine is the irreversible complex between serum proteins and 
glucose. Fructosamine depend on protein half-life and usually reflects glucose 
concentrations during the last 1-2 weeks; and so it is not affected by acute 
stress hyperglycaemia (Link & Rand, 2008; Crenshaw et al., 1996). 
There has been an interest in developing prognostic markers for feline DM. 
Insulin concentrations at DM diagnosis are usually low, and do not predict 
whether cats go into remission or not (Tschuor et al., 2011; Nelson et al., 
1999). In one study of non-diabetic cats, fasting insulin was used to detect 
reduced insulin sensitivity (Appleton et al., 2005). In that study it was 
proposed that cats with reduced insulin sensitivity could be at risk for 
developing type 2 DM and identifying these cats would enable preventive 
actions.  
2.1.2 Treatment 
To achieve remission of DM in cats it is recommended that insulin treatment is 
started promptly to decrease blood glucose and hence reverse glucotoxicity. 
Since lente insulin has a suboptimal duration of action, the longer acting 
glargine has been recommended as the first line of therapy in cats with DM 
(Rucinsky et al., 2010). Even if glargine is prescribed, cats typically require 
insulin twice a day to achieve glycaemic control.  
Cats are strict carnivores, and low carbohydrate and high protein diets, 
together with insulin have been found useful and are recommended for 
achieving glycaemic control in diabetic cats (Sparkes et al., 2015; Rucinsky et 
al., 2010).  
Oral hypoglycaemic agents are ineffective in most diabetic cats (Palm & 
Feldman, 2013). When they are used, a sulfonylurea, which increase insulin 
secretion from beta cells, is the most common choice. However, if the beta 
cells are incapable of producing insulin the drug has little effect. Another 
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concern has been that increased insulin secretion stimulated by sulfonylureas is 
accompanied by amyloid deposition in the pancreas which may further reduce 
beta cell function (Palm & Feldman, 2013).  
2.2 Acromegaly 
Acromegaly in cats is caused by a GH-secreting pituitary adenoma (Rijnberk et 
al., 2003). GH is an insulin antagonist and insulin resistant DM is typically 
found in acromegalic cats (Niessen, 2010). At presentation acromegalic cats 
may have clubbed paws, broad facial features, prognathism and organomegaly. 
However, in contrast to dogs, clinical signs may not be prominent, especially 
not early in the disease. A typical finding in diabetic cats is weight gain in the 
face of poor glycaemic control, which would usually have been accompanied 
by weight loss (Niessen, 2013). 
2.2.1 Diagnosis 
IGF-I is generally considered a screening marker for acromegaly in cats with a 
cut-off of 1000 ng/mL used for further investigation (Niessen, 2013). Clinical 
signs may not be prominent and one can only be truly confident of a diagnosis 
of acromegaly where pituitary tissue is available for immunohistochemistry. In 
humans with acromegaly, lack of GH suppression in response to an oral 
glucose load is an aid in diagnosis (Giustina et al., 2010). However, in healthy 
cats given glucose intravenously there is no effect on GH secretion (Kokka et 
al., 1971).  
Diagnostic imaging (computed tomography, CT, and magnetic resonance 
imaging, MRI) are often used in the diagnostic workup. However, the 
incidence of pituitary “incidentalomas” is unknown in cats: in humans the 
prevalence is estimated to be approximately 9% (Orija et al., 2012). In my 
opinion there are no studies to date that been designed in a way that identifies 
the best IGF-I cut-off for acromegaly. Recently a claim has been made that 
there is a prevalence of acromegaly of 25% in diabetic cats in the United 
Kingdom (Niessen et al., 2015). This was based on screening 1221 cats and 
identifying 319 cats with IGF-I >1000 ng/mL. Of these, 63 were further 
investigated and 60 were diagnosed with acromegaly based on diagnostic 
imaging or post-mortem examination. In the study by Niessen (2015) the 
number of cats with pituitary abnormalities on diagnostic imaging appears very 
high. It would be interesting to know the prevalence of pituitary abnormalities 
in a wider population of cats with and without DM. 
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2.2.2 Treatment 
Specific treatment for acromegaly in cats consists of hypophysectomy or 
radiotherapy (Niessen, 2013), options that are not yet available in Sweden. The 
most common approach for managing acromegalic cats is to tailor insulin 
dosages. Somatostatin analogs have been tried in cats. Octreotide has had 
mainly disappointing results (Slingerland et al., 2008; Peterson et al., 1990). 
Pasireotide has shown more promising results with a decrease of IGF-I in 12 
acromegalic cats after treatment (Scudder et al., 2015); more studies are 
needed before this treatment can be widely recommended.  
  
21 
3 Validation of analytical methods 
In veterinary medicine assays intended for humans are often used for other 
species. It is therefore particularly important to validate each analytical 
method. The cost of developing species-specific immunoassays for many 
hormones used in the diagnosis of rare diseases is too high to be affordable for 
the veterinary laboratory, because the cost is ultimately borne by the animal 
owners. Nevertheless, the assays must provide reliable results. When analysing 
IGF-I, interference of IGFBPs can substantially influence test results and it is 
especially important that validation of the method focuses on this problem. 
The uncertainty of a test result can be due to preanalytical-, analytical- or 
postanalytical errors. Pre- and postanalytical errors can be reduced by 
standardization of routines and correct sample handling but these are still 
considered major sources of variation (Wiwanitkit, 2001). The analytical errors 
are often divided into random and systematic error, and can be expressed 
separately or combined. There are different approaches to dealing with the 
concept of error. Total error (TE) is advocated by Westgard and colleagues 
(2008) and describes the probability distribution around a true concentration. 
To calculate TE the systematic error and the random error are combined to a 
total error. The observed TE is often compared to the allowable total error 
(TEa) which can for example be based on biological variation or clinicians’ 
expertise (Westgard, 2008). In another approach, “Uncertainty”, used by the 
International Organization for Standardization (ISO) expresses the dispersion 
of values during measurement (JCGM, 2008). With this approach it is 
recommended that different sources of uncertainties are identified, combined 
and preferably the systematic error corrected. Often the expanded uncertainty 
is calculated and this corresponds to a confidence interval for the measured 
value (JCGM, 2008).  
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3.1 Random error - precision 
Random error can be evaluated from repeated measurements and is often 
expressed as coefficient of variation (CV). In many clinical laboratories 
measurements of precision are often expressed as CV within and between 
analytical runs. It is possible to take this further, for example to evaluate 
between run CV during longer time periods using different batches or to 
calculate CV between laboratories. For clinicians it is useful to know total CV 
because they often compare samples analysed on different days. One 
recommendation from the Clinical and Laboratory Standards Institute (CLSI) 
is to run 5 replicates on 5 days and evaluate results based on an ANOVA 
(CLSI, 2014). Precision may differ depending on concentrations and should be 
evaluated at different concentrations.  
3.2 Systematic error 
3.2.1 Bias 
Bias is defined as systematic deviation from the true value. Bias can be 
investigated by analysing reference material, recovery of spiked samples or 
comparison with a gold standard method (Magnusson & Örnemark, 2014). In 
veterinary medicine there are very few species-specific reference solutions that 
can be used as quality controls or for spiking, or gold standard methods for 
comparison, and true bias is seldom evaluated. Guidelines from the American 
Society for Veterinary Clinical Pathology recommend that veterinary 
laboratories should determine the observed TE by combining precision and 
bias, and these values can be derived from quality control material (ASVCP, 
2013). Most quality control material used in veterinary medicine is not species-
specific and it is therefore difficult to express bias as deviation from the true 
value. Clinical laboratories that set their own reference intervals for a given 
assay already include possible bias into the reference intervals. 
Identifying all essential sources of variation is important but may be 
difficult. There are reports that sample positioning on ELISA plates can 
contribute to systematic errors (Miller et al., 2009; Shekarchi et al., 1984) but 
including or identifying this effect in validation studies is seldom undertaken.  
3.2.2 Dilution experiments 
Dilution of samples is sometimes performed with the objective to investigate 
whether there is a linear relationship between the dilution factor and 
concentration. This problem is discussed in a guide from CLSI, where it is 
recommended that at least five dilutions in 2-4 replicates are analysed and a 
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first, second- and third order polynomial curve fitted to the data (NCCLS, 
2003). If second or third order polynomial curve fits better than a linear one, 
the assay is considered non-linear in statistical terms. To evaluate the degree of 
non-linear error the difference between the linear and the non-linear curve is 
calculated and this value compared to predetermined limits. It has been 
proposed that TEa can be used as an acceptable limit for non-linear error 
(Westgard, 2008). 
Another approach to express agreement of results from dilution experiments 
is to investigate consistency after dilution. The undiluted sample is usually 
considered the true value. The ratio between the expected value (E) and the 
observed value (O) can be used for evaluating consistency and is often 
expressed as a percentage. For example, in a dilution experiment with 
negligible random error and perfect consistency, the O/E ratio will be 100% at 
all dilution points after adjusting for dilution factors. 
3.2.3 Interference 
Interfering substances can cause erroneous results during analysis. IGFBPs 
have been identified in feline serum (Lewitt et al., 2000; Maxwell et al., 1999) 
and are likely to potentially interfere during analysis as in other species. When 
analysing IGF-I the IGFBPs may cause bias leading to either false low or false 
high concentrations depending on which assay is used (Frystyk et al., 2010). 
When validating IGF-I assays for use with human samples it has been 
recommended that serum samples from a variety of clinical conditions, in 
which IGFBP concentrations or profiles may potentially affect IGF-I assay 
results, are included; information about this interference should be reported to 
the end user (Clemmons, 2011). The gold standard procedure for removing 
IGFBPs is size-exclusion chromatography under acidic conditions (Clemmons, 
2011). This is a cumbersome procedure and may not be feasible in routine 
practice. Instead other procedures have been developed to remove IGFBPs, for 
example acid-ethanol extraction and acid-ethanol followed by 
cryoprecipitation. In many species these extraction methods do not remove all 
IGFBPs and these may interfere in the assay (Mohan & Baylink, 1995; Frey et 
al., 1994; Srivenugopal et al., 1994). In competitive immunoassays truncated 
IGF-I with reduced affinity for IGFBPs has been effectively used (Bang et al., 
1991). Another approach is to add excess amounts of IGF-II (Frystyk et al., 
2010). The sample is acidified to dissociate IGFs from their binding proteins 
and excess amounts of IGF-II, which does not interact with the IGF-I antibody, 
are added to the sample. When the sample is neutralized again, the excess IGF-
II binds to the IGFBPs thus reducing their availability for interference in the 
assay. To determine interference exogenous IGFBPs can be added to serum 
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samples and interference calculated. Recommendations for human samples are 
to add IGFBP-2 and -3, up to twice the reference limit (Clemmons, 2011). No 
reference interval (RI) for any of the six feline IGFBPs has been reported and 
there are no purified feline IGFBPs available. 
Insulin assays are subjected to interference by insulin antibodies. Diabetic 
cats treated with insulin may develop insulin-antibodies (Hoenig et al., 2000) 
and these are a potential source of interference in insulin immunoassays. One 
group has reported that insulin auto-antibodies exist in healthy cats (Takashima 
et al., 2013; Nishii et al., 2010). 
3.3 Biological variation and assay performance 
In addition to preanalytical, analytical and postanalytical variation, repeated 
test results from an individual animal vary depending biological factors. Most 
analytes vary similarly in health and disease; however, for some analytes 
disease status may affect variation (Borai et al., 2013; Ricós et al., 2007). 
Biological variation can be classified into within-individual variation (CVI) and 
between-individual variation (CVG). 
3.3.1 Quality specifications 
In 1999 there was a conference in Stockholm addressing quality specifications 
for analytical performance. A hierarchic model was proposed in which quality 
specifications based on biological variation was considered high in the 
hierarchy (Kenny et al., 1999).  
To decide quality specifications and the acceptable uncertainty for 
analytical assays it should be decided what effect different magnitudes of 
variation have on decision making for a specific test. If we ignore preanalytical 
and postanalytical variation, total variation for an analyte would consist of 
analytical variation (CVA) and biological variation. Based on data from 
biological variation suggested limits for optimal, desirable and minimal CVA 
are calculated as: optimal CVA <0.25CVI; desirable CVA<0.5CVI; minimum 
CVA<0.75CVI. These limits for CVA have been calculated to add 3.1, 11.8 and 
25.0 %, respectively, to test result variability (Fraser, 2001). 
In a similar manner, recommendations for acceptable bias have been 
proposed. If RI is not determined by the laboratory, the assay bias affects the 
number of individuals that fall within the RI being used. RI usually include the 
central 95% of the reference population. If bias is positive, more than 2.5% of 
individuals would be above the upper reference limit and less than 2.5%, 
below. It has been proposed that desirable bias should be less than 
0.25(CVI2+CVG2)0.5 so that 5.8% are outside the RI instead of the usual 5% 
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(Fraser, 2001). Westgard and Fraser suggests that TEa can be calculated using 
limits for CVA and bias derived from biological variation (Westgard, 2008; 
Fraser, 2001). The use of TEa is recommended by the American Society for 
Veterinary Clinical Pathologists (ASVCP, 2013; Harr et al., 2013).  
3.3.2 Reference intervals and repeated sampling 
For analytes that have a marked individuality (i.e. CVI is considerably lower 
than CVG), population-based RI may be of limited utility for follow-up of 
patients (Fraser & Harris, 1989). In these cases a significant change of an 
analyte for that individual may not be detected because the value does not 
exceed the reference limits. The utility of population-based RI can be evaluated 
by an index of individuality (INDI) which is calculated as 
(CVA2+CVI2)0.5/CVG. If INDI <0.6 the use of populations-based RI may be of 
limited use and subject-based RI are recommended. If INDI is between 0.7 and 
1.4, population-based RI can be used but with caution, and for INDI >1.4 
observed values can be interpreted with respect to population-based RI 
(Walton, 2012). If INDI indicates that population based RI are too wide, 
stratification for example by age or gender, may improve its utility. 
Animals are often sampled multiple times to evaluate change of treatment 
or progress of disease. Since test result variability in one animal depends on 
CVI and CVA, it is possible to calculate the magnitude of change in test results 
considered to be significant. This value is usually expressed as a Reference 
Change Value (RCV) and is based on CVA, CVI and the desirable level of 
significance. For example a bi-directional change between two samples and 
95% probability is calculated as 1.96(2(CVA2+CVI2))0.5 (Walton, 2012; Fraser, 
2001). 
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4 Aims of the thesis 
The general aim was to determine factors regulating feline IGF-I 
concentrations in health and disease. 
 
Specific aims were: 
 
? To validate assays for measurement of feline serum IGF-I and 
feline serum insulin, including determination of biological 
variation. 
 
? To determine the range of IGF-I concentrations in cats. 
 
? To determine factors contributing to circulating IGF-I 
concentrations, including IGF-binding forms, in order to improve 
interpretation of test results for feline medicine. 
 
? To investigate the effect of diabetes mellitus on IGF-I 
concentrations at diagnosis and during insulin treatment in cats. 
 
? To investigate the role of IGF-I and insulin in predicting remission 
of feline diabetes mellitus. 
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5 Materials and methods 
5.1 Animals 
Healthy and diabetic cats were recruited by advertising at a cat exhibition and 
the reception area at Bagarmossen Animal Hospital, and by sending e-mails to 
all staff at Bagarmossen Animal Hospital, the University Animal Hospital and 
the Department of Clinical Science. Cats were considered healthy based on 
answers to a health questionnaire by owners, a clinical examination by a 
veterinarian and a biochemical profile. Cats were excluded if they were 
pregnant or under one year of age. For cats sampled solely for these studies, 
animals were excluded if they were stressed as exhibited by hissing and 
struggling. Diabetes mellitus was diagnosed based on clinical signs, 
hyperglycemia, glucosuria and elevated fructosamine. Cats were fasted for 12h 
before sampling, except for Manuscript IV where cats on insulin treatment 
were fasted for 5-12h. In addition, left-over serum from samples submitted for 
investigation to the Clinical Pathology Laboratory, University Animal 
Hospital, Swedish University of Agricultural Sciences, were used for 
validation experiments (Paper I, II, IV). All serum samples were centrifuged 
within one hour after sampling. 
 In total, 60 healthy and 44 diabetic cats were sampled during the study 
period of Papers I and II and Manuscripts III and IV. Of the 44 diabetic cats 3 
were diagnosed with acromegaly based on clinical signs, high IGF-I 
concentrations and a pituitary tumour detected at post mortem examination or 
computed tomography (CT). The cat in which CT was used for detecting a 
tumour was later subjected to post mortem examination and was found to have 
a pituitary adenoma. Of the 60 healthy cats, five had abnormal biochemical 
results, clinical findings or missing information and were excluded, leaving 55 
healthy cats. 
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In Paper I, 36 healthy cats and 22 diabetic cats were included. Ten of these 
healthy cats were subjected to an oral glucose tolerance test (OGTT). Baseline 
sampling was performed with a permanent catheter placed in the cephalic vein 
from which blood samples were withdrawn at 30 and 60 minutes.  
In Paper II 55 healthy cats, four cats with DM, three cats with DM and 
acromegaly, one cat with chronic renal failure and two cats with liver disease 
were included. Chronic renal failure was diagnosed based on clinical signs, 
ultrasonography and azotemia. Liver disease was diagnosed by elevated liver 
enzyme activity, increased bile acids and histopathological findings (hepatic 
lipidosis and biliary liver cirrhosis). 
Ten healthy cats and one acromegalic cat were enrolled in the study of 
biological variation (II and Section 6.3). One healthy cat had a heart murmur 
and two cats were stressed during sampling. Cats excluded due to stress were 
not sampled at later occasions. Thus one acromegalic and seven healthy cats 
completed the study period. Cats were sampled from the cephalic vein, in their 
home environment in the morning after a 12h fast, once a week for five weeks 
(sample occasion A-E) by the same veterinarian using the same equipment 
each time.  
For Manuscript III, 41 diabetic cats and 55 healthy cats were included. 
Samples for size-exclusion chromatography were selected to represent a range 
of age and IGF-I concentrations in both healthy (n=13) and diabetic (n=10) 
cats. 
For Manuscript IV, 24 diabetic cats were included and were sampled five 
times over the course of one year from diagnosis (T0=at diagnosis, T1=2-4 
weeks, T2=8-10 weeks, T3=5-7 months, T4=10-13 months). Serum for size-
exclusion chromatography in this study was selected from cats that went into 
remission (n=3) and cats that did not (n=4). Serum from the three cats used for 
chromatography and which went into remission were also subjected to 
measurement by mass spectrometry. 
5.2 ELISA validation 
5.2.1 Feline insulin ELISA 
Paper I validated the Mercodia Feline Insulin ELISA (Uppsala, Sweden) which 
is a commercial sandwich ELISA. The wells of the plate are coated with mouse 
monoclonal anti-human insulin antibodies and a second monoclonal antibody 
is used for detection. In the beginning of the study this assay used standards 
based on human insulin but during the validation process the manufacturer 
changed standards to feline origin. Cross-reactivity for insulin glargine 
(Lantus) and lente insulin (Caninsulin) reported by the manufacturer was 8.4% 
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and 57.4%, respectively (Mercodia, 2008). All the samples were pipetted 
within the 30 minutes recommended by the manufacturer. 
Position effects were evaluated by pipetting the same standard in all wells 
and results evaluated by two-way ANOVA with rows and columns as factors. 
This was further investigated by evaluating precision and position effects by 
pipetting samples with low, medium and high insulin concentrations in three 
fixed duplicate positions on the ELISA plate. The assay was run on 8 different 
days and results evaluated by two-way ANOVA with microplates and positions 
as factors. Feline insulin extracted from a feline pancreas, as described in Paper 
I, was used to develop a solution for spiking studies.  
Consistency upon dilution was evaluated by diluting samples up to 1:8 with 
the zero calibrator as recommended by the manufacturer. The expected 
concentration, E, was calculated from the original concentration and the 
dilution factor or the spiking procedure. O denotes the observed concentration 
for the spiked or diluted sample, and the result was expressed by the ratio O/E. 
The standard error of O/E was calculated from the estimated values of different 
components of variation (I, supplement). To test the hypothesis of consistency, 
the critical limit was obtained by multiplying the standard error by k (coverage 
factor, Paper I, Appendix). According to recommendations for situations when 
the standard error is very uncertain, k was set to 3 (JCGM, 2008).  
Stability was evaluated by analysing insulin concentrations on samples 
stored at room temperature (20°C) and in the refrigerator (2-8°C) daily for four 
days. The critical limit, based on the expanded uncertainty of the assay, was 
calculated as described in detail in the appendix for Paper I. 
To test utility of the insulin assay in measuring a known biological response 
samples from an OGTT were assayed. Glucose (dextrose 500 mg/mL) 1 g/kg 
body weight was given as a solution orally by syringe at the hospital. Insulin 
(I) and glucose (Section 6.1) were measured at baseline and after 30 and 60 
minutes. Statistical analyses were performed using Wilcoxon signed-rank test. 
Insulin concentrations between healthy and diabetic cats were compared by 
Mann-Whitney test. 
5.2.2 IGF-I ELISA 
The Mediagnost IGF-I ELISA (Reutlingen, Germany) was validated and 
presented in Paper II. Although this assay is intended for human use it is stated 
in the instructions that the assay can be used in various species, including cats. 
It uses a sandwich technique based on two specific high-affinity antibodies. 
The sample is first diluted with an acidic buffer containing excess IGF-II. The 
acidic buffer destroys ALS and dissociates IGFs from their IGFBPs allowing 
the excess IGF-II to later associate with IGFBPs when neutralized. The plates 
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are coated with monoclonal anti-human IGF-I antibodies to which the second 
polyclonal biotinylated antibody is added. When the sample is pipetted into the 
wells it is neutralized by the antibody conjugate and the excess IGF-II binds to 
the IGFBPs, leaving IGF-I free to interact with the antibodies. Standards were 
recombinant human IGF-I calibrated against WHO reference material 02/254.  
Position effect was evaluated by pipetting a high control sample in all wells. 
When pipetting samples into this ELISA plate, all samples were positioned in 
duplicates situated in adjacent wells overlapping two columns. Hence, the 
mean value of duplicates was evaluated by two-way ANOVA with rows and 
columns as factors. Precision was determined by analyzing samples with low, 
medium and high concentrations in 2-20 replicates on 8 days. Statistical 
calculations were performed taking the uneven number of replicates into 
account (Aronsson & Groth, 1984). Spiking was done by adding recombinant 
human IGF-I (CU100, IBT Systems, Binzwangen, Germany). 
 Linearity after dilution was evaluated by diluting five feline serum 
samples, as well as a serum sample that had been subjected to size-exclusion 
chromatography under acidic conditions in order to remove IGFBPs. Results 
were evaluated according to CLSI and Westgard (Westgard, 2008; NCCLS, 
2003). In addition to this, sera from 16 cats were serially diluted 4 times. In 2 
dilution experiments the samples were analyzed both with and without added 
recombinant human IGFBPs. In the first experiment a total concentration of 30 
mg/L was added: 10 mg/L of BP-1 (871-B1-025; R&D Systems, Oxfordshire, 
UK), 10 mg/L of BP-2 (674-B2-025; R&D Systems) and 10 mg/L of BP-3 (10-
663-45149; Genway, San Diego, CA, USA). The samples were incubated at 
room temperature for 3h before analysis. In the second experiment 8 mg/L was 
added (1 mg/L of BP-1, 2 mg/L of BP-2 and 5 mg/L of BP-3).  
Stability of IGF-I (IV) was determined by analysing 2 samples stored at 
room temperature and in refrigerator at day 0, 3, 6 and 14. In one cat there was 
insufficient serum stored at 20°C and 6 days was the longest storage time.  
5.2.3 Biological variation 
Biological variation of IGF-I is presented in Paper II. The biological variation 
of insulin has not been included in any paper or manuscript. Outliers between 
replicates and within cats were tested by Cochran’s test and between cats by 
Reed’s criterion (Fraser & Harris, 1989).  Data was analysed using nested 
ANOVA with both balanced and unbalanced designs. Variances for between 
cats, within cats and between replicates were obtained by using nested 
ANOVA by the command “proc nested” in SAS (SAS 9.3 SAS Institute Inc., 
Cary, NC, US). The variances and overall mean were used to calculate the 
corresponding CVs (CVG, CVI, and CVA). 
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For insulin there was not enough serum for duplicate analysis from one 
occasion in one cat (sample occasion A). Results of the remaining samples 
indicated one sample occasion as an outlier in another cat and hence that 
sample occasion was also deleted (sample occasion A). Hence the balanced 
design was based on excluding all A samples, leaving seven cats and four 
sampling occasions. The results are presented in Section 6.3. 
For IGF-I, one duplicate in one cat was considered an outlier. To achieve a 
correct design for the balanced ANOVA two approaches were used: 1) this 
sample number was excluded in all cats, or 2) the cat was excluded from 
analysis. The first approach is presented in Paper II and the second approach in 
Section 6.3. 
By using CVG, CVI and CVA from the method validations at relevant 
concentrations, the reference change value was calculated as 
1.96(2(CVA2+CVI2))0.5 and index of individuality as (CVA2+CVI2)0.5/CVG. 
Desirable limit for TEa was calculated as 1.65(0.5CVI)+ 0.250(CVI2+CVG2)0.5 
(Harr et al., 2013; Friedrichs et al., 2012; Walton, 2012; Fraser, 2001). 
5.3 Size-exclusion chromatography for IGFs and IGFBPs 
Size-exclusion chromatography is a useful technique to separate proteins. 
Under acidic conditions, ALS is destroyed and IGFBPs dissociate from IGFs. 
Size-exclusion chromatography under acidic conditions, with a column that 
can separate proteins with molecular sizes of IGFBPs (about 24-50 kDa) and 
IGFs (about 7.6 kDa), is considered gold standard method for separating 
IGFBPs from IGFs (Clemmons, 2011).  
Size-exclusion chromatography under neutral conditions will separate the 
ternary (approximately 150kDa) and binary (approximately 30-50kDa) 
complexes, as well as free IGF-I. To detect these complexes, concentrations of 
IGFs or IGFBPs can be measured directly in the eluted fractions. Alternatively, 
tracer amounts of iodinated IGF-I or IGF–II can be used, by addition to serum 
and then incubating to equilibrium so that incorporation of label reflects the 
pattern of endogenous IGF-binding proteins. After size-exclusion 
chromatography radioactivity (counts per minute, C.P.M.) in the fractions is 
then detected by gamma-counting (Renes et al., 2014; van Duyvenvoorde et 
al., 2008; Lewitt et al., 2001; Lewitt et al., 2000). 
5.3.1 Acidic conditions 
Size-exclusion chromatography under acidic conditions on a Superdex column 
(17-5174-01; GE Healthcare, Little Chalfont, UK) was used for separating 
IGFBPs from IGFs in Paper II. Serum from a healthy cat as well as from cats 
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with DM and acromegaly, chronic renal failure and liver cirrhosis was used for 
this experiment. Firstly serum (100 ?L) was incubated with 400 ?L of 1.25 M 
acetic acid and chromatographed with 1 M acetic acid as running buffer as 
recommended (Mohan & Baylink, 1995). However, under these conditions and 
using feline serum there was a precipitate and lower IGF-I immunoreactivity 
than when 1 M acetic acid was used. Thus 100 ?L feline serum or recombinant 
human IGF-I was instead mixed with 400 ?L 1 M acetic acid and incubated for 
30 min. Although no particles were macroscopically visible the sample was 
filtered (Whatman rezist, 0.2 ?m) to remove any remaining particulate matter 
before loaded onto the column. Recombinant human IGF-I was 
chromatographed and used for comparison. 
The samples were eluted at 0.5 mL/min using 1 M acetic acid as running 
buffer. To determine when IGF-I eluted, fractions were collected every two 
minutes and lyophilized (SpeedVac) before being analysed in the IGF-I 
ELISA. In addition, size-exclusion chromatography was performed on feline 
serum and fractions known to be positive for IGF-I immunoreactivity were 
pooled and dried. The immunoreactivity of the pooled fractions was compared 
to that in the loading material. Insoluble material was visible after 
lyophilisation and reconstitution of the loading material, therefore the volume 
was reduced to concentrate the samples and the volumes adjusted to 
equivalence.  
The immunoreactivity of IGF-I in the sample before and after size-
exclusion chromatography was determined by the IGF-I ELISA. The sample 
after size-exclusion chromatography was used as expected (E) and was 
compared to the non-chromatographed sample (O). 
5.3.2 Neutral conditions 
In Manuscript III and IV size-exclusion chromatography under neutral 
conditions was used to separate IGF-binding forms in serum. A Superose 
column (17-5173-01; GE Healthcare) was used to separate feline serum 
incubated with human h-125I-IGF-II, as well as size-separation of non-labelled 
serum. Feline serum (50?L) was incubated with 50?L PBS-buffer (50 mM, pH 
7.4) and 100 000 C.P.M. h-125I-IGF-II (1096 Ci/mmol, T-033-23, Phoenix 
Pharmaceuticals, CA, US) until equilibrium (>17h at 4°C). The tubes were 
centrifuged at 10 000 G and the supernatant loaded onto the column. In total, 
25 ?L serum in a final volume of 100 ?L of PBS were loaded on the column 
and eluted at 0.5 mL/min. Running buffer was PBS (50 mM, pH 7.4) run at 0.5 
mL/min and fractions collected every 0.5 minutes. The C.P.M. for each 
fraction was counted in the gamma counter (Wallac Wizard-2 2470, Perkin 
Elmer, Massachusetts, USA).  
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Since the affinities of feline IGFs and IGFBPs are unknown and may differ 
from human IGFs, the 150kDa and 30-50kDa peaks were expressed as a 
150/30-50kDa ratio, estimated as a ratio of the sums of the five top-fractions 
for the 150kDa peak and 30-50kDa peak, respectively. 
In Manuscript III size-exclusion chromatography of non-labelled serum was 
performed and IGF-I immunoreactivity determined by ELISA. Serum (100 ?L) 
was diluted with 100 ?L of ammonium acetate (0.2 M, pH 7.4). The column 
was run at 0.5 mL/min and fractions collected every two minutes. Fractions 
were lyophilized, reconstituted with assay buffer containing IGF-II and 
analysed in the IGF-I ELISA. Molecular weight markers (HWM 24-4038-42, 
and LMW 28-4038-41, GE Healthcare, Uppsala, Sweden) showed the same 
elution patterns in PBS and ammonium acetate. In Manuscript IV changes in 
the 150/30-50kDa complex between T0 and T1 was evaluated by paired t-test 
after transformation to the natural logarithmic scale. 
5.4 SDS-PAGE and Western ligand blots of IGFBPs 
In Paper II, in order to visualize IGFBPs in fractions after size-exclusion 
chromatography under acidic conditions, sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed under reduced 
conditions, followed by WLB. In this thesis SDS-PAGE under non-reduced 
conditions is also reported. Fractions from size-exclusion chromatography 
under acidic conditions were lyophilized and reconstituted with 100 ?L 
distilled water. The reconstituted fractions were diluted 50% with Laemmli 
buffer, with or without mercaptoethanol, and 15 ?L loaded on to a TGX gel 
(Any kD, BioRad, Hercules, CA, USA). On every gel a molecular weight 
marker was loaded (Precision Plus Protein Western C Standards, 1610376 or 
Precision Plus Protein Dual Xtra Standards, 1610377, BioRad). SDS-PAGE 
was run at 100 V (Mini-Protean Tetra Cell, BioRad). The proteins were 
transferred to nitrocellulose membrane (0.2 ?m) at 100 V for 1h in the cold 
room (Mini-Trans-blot, BioRad). Membranes were incubated with biotinylated 
IGF-II (1:2500, FU100, IBT-systems) overnight in the cold room. The 
membrane was washed and neutravidin-HRP (1:5000, high sensitivity 
neutravidin-HRP, Pierce, ThermoFischer Scientific, MA, US) was added and 
incubated for 1h. If the Western C standard was run as weight marker 
StrepTactin-HRP (1:30 000, Precision Protein™ StrepTactin-HRP Conjugate, 
1610381, BioRad) was added together with the neutravidin-HRP. After 
washing protein bands were detected by using Amershams ECL Prime (GE 
Healthcare). 
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5.5 Mass spectrometry 
A targeted mass spectrometry based method (MS) with parallel reaction 
monitoring (PRM) analysis, previously validated for cats (Sundberg, 2015) was 
used to measure IGF-I, IGF-II, IGFBP-3, and IGFBP-5 in Manuscript IV. 
These analyses were performed in serum at baseline (T0) and after 2-4 weeks 
(T1) from three cats that went into remission. The method is described in detail 
elsewhere (Sundberg, 2015). Briefly, protein content of serum was measured 
with the Bradford protein assay (BioRad Laboratories, Hercules, CA, US) and 
an aliquot equal to 35 ?g was used for digestion. To quantify the proteins, 
reference peptides (QPrEST, Atlas antibodies, Stockholm, Sweden) were used. 
QPrESTs are recombinantly produced human protein fragments, with heavy 
labelled arginine and lysine, also containing the peptides of interest, in this 
case sequences of feline IGF-II, IGFBP-3 and IGFBP-5. For IGF-I one stable 
isotope label peptide containing the feline IGF-I amino acid sequence (New 
England Peptide, Gardner, MA, US) was used as standard instead of QPrEST 
peptides. The serum samples were spiked with QPrEST and peptide to a 
concentration of 1 fmol/?L for IGF-I, IGFBP-3 and IGFBP-5, and 3 fmol/?l 
for IGF-II and digested with trypsin (5% w/w). Samples were incubated 
overnight at 37°C, desalted on a ZipTip C18 column (Merck Millipore) and 
dried in SpeedVac system. After reconstitution, peptides in the samples were 
separated on a reverse-phase column using an EASY-nLC 1000 system 
(ThermoFischer Scientific) followed by a PRM analysis on a Q Exactive 
Orbitrap Plus mass spectrometer (ThermoFischer Scientific). For data analysis 
and quantification the Skyline software was used. In Manuscript IV changes in 
IGFBP-3, IGFBP-5 and IGF-II between T0 and T1 were evaluated by paired t-
test after transformation to the natural logarithmic scale. 
5.6 Multivariable and logistic regressions 
In Paper II and Manuscript III predictors of IGF-I concentrations were assessed 
by multivariable linear regression models using Minitab (II, Minitab 16, State 
College, PA, USA) or the “proc GLM” command in SAS 9.3 (III, SAS 
Institute Inc., Cary, NC, US). Explanatory variables in Paper II were weight, 
age and sex. In Manuscript III explanatory variables were weight, insulin and 
age. Assumptions of normality, homoscedasticity and linear relationship 
between variables were evaluated by QQ-plots, histograms and plotting 
standardized residuals against the predicted values. If preliminary models 
showed violation of assumptions, predictors and/or dependent variables were 
transformed to the natural logarithmic scale. Significance was set to P<0.05. 
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In Manuscript IV, a linear mixed-effect model was built to evaluate factors 
associated with IGF-I concentrations using the statistical software R (The 
statistical software R, 2014) . Explanatory variables were age, days from 
initiation of insulin treatment, insulin, fructosamine, body condition score 1-5 
(1=underweight and 5=overweight), and weight. The individual cat was 
considered a random effect and the other variables as fixed effects. Akaike 
Information Criteria and p-values were evaluated during modelling and 
predictors not significantly contributing (p>0.10) were excluded in the final 
model. Residuals were evaluated for normal distribution, homoscedasticity and 
linearity with respect to the predictors. If preliminary models showed non-
normality of residuals the predictors were transformed to the natural 
logarithmic scale. 
Predictors of remission were evaluated by logistic regression and receiver 
operating characteristic (ROC) curves calculating area under the curve (AUC) 
using the statistical software R. Samples after 2-4 weeks (T1) were considered 
to give the highest statistical power based on the number of animals and 
differences between groups. Since glycaemic control has been associated with 
remission rates (Gottlieb & Rand, 2013), glucose, fructosamine and insulin 
were considered potential predictors for remission in addition to IGF-I.  
  
 
39 
6 Results 
6.1 Validation of a feline insulin ELISA 
In paper I there was a significant effect of sample positioning on the ELISA 
plate that was dependent on columns. During experiments where standard was 
pipetted into all wells this column effect was still present after pipetting in 
reverse order, the plate being washed in reverse order and when columns were 
randomized but analyses performed on the original column order. Position 
effect was also present when analysing serum samples in duplicate in 
three different positions on 8 different days. Total-, intra-,? ??? inter-
assay ??? ??? ????? ??? position effect is presented in Table 1. 
Table 1. Assigned values for CVs depending on insulin concentrations. CVM indicates the CV 
between microplates; CVL, systematic and random position effect; CVe, the CV between 
duplicates; CVTot(2), total CV for the mean values of duplicates. 
Insulin concentrations (ng/L) 
<50 50-100 100-200 >200
CVM 15.0 13.0 8.0 8.0
CVL 10.0 10.0 6.0 8.0
CVe 10.0 6.0 2.0 2.0
CVTot(2) 19.4 16.9 10.1 11.4
When using human insulin standard, the absorbance in the blank well often 
overlapped the first standard point. This was not seen with feline standard 
however the concentration of the lowest standard also increased. 
Serum spiked with purified feline insulin yielded an O/E ratio of 86-126% 
and consistency after dilution of plain serum was 78-105%. This was within 
the defined critical limits (Paper I). Fasting insulin concentrations in healthy 
cats demonstrated a wide range of values. Insulin concentrations in 35 out of 
36 cats were 31.0-652 ng/L (median 221 ng/L). Diabetic cats had median 
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insulin concentrations of 60 ng/L (range <5-321 ng/L), significantly lower than 
in healthy cats (p<0.0001). One healthy cat had an insulin concentration of 
2139 ng/L. To investigate the presence of natural anti-insulin antibodies in 
healthy cats others have added purified insulin to serum. In presence of natural 
insulin-antibodies the recovery after addition has been poor (Nishii et al., 
2010). The serum sample with high insulin concentration was spiked with 
feline insulin. The results demonstrated acceptable recovery (80-90%).  
The insulin concentrations measured in feline serum increased after an oral 
glucose tolerance test consistent with the biological response. There was a 
significant increase of insulin after 30 and 60 minutes compared to baseline but 
no significant differences between 30 and 60 minutes (I) despite a further 
increase in glucose. Glucose concentrations after OGTT have not been 
presented in any paper or manuscript (Figure 1). 
 
 
Figure 1.Serum insulin and glucose concentrations in 10 healthy cats after oral glucose tolerance 
test. Whiskers indicate max and min concentrations. *, p<0.05; **, p<0.01, compared to baseline. 
§§, p<0.01 compared to 30 minutes. 
For samples stored at 20°C, insulin concentrations were within the 
calculated critical limit for up to 3 days. However, there was a significant 
difference at day 2 between samples stored at 20°C and 2-8°C, and hence 
samples stored at 20°C were considered stable for 1 day. 
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6.2 Validation of an IGF-I ELISA for use in cats 
No significant row or column effect (p=0.11) was detected in the IGF-I ELISA 
(II). Total-, intra- and inter-CV are presented in Table 2. 
 
Table 2. Coefficients of variation (CV) expressed in percent (%). Results were derived by 
analysing samples in 2-20 replicates on 8 different days. Results were obtained by use of 
ANOVA. 
Concentration 
(ng/mL) 
Total CV (%) Intra-assay CV (%) Inter-assay CV (%) 
86 6.4 4.8 4.3 
442 4.3 2.4 3.6 
843 5.8 3.1 5.0 
 
Results after dilution of serum samples were considered non-linear 
according to CLSI. Non-linearity was considered dependent on IGFBPs since 
samples diluted with more IGF-II containing assay buffer were linear and a 
sample previously considered non-linear was linear after size-exclusion 
chromatography. If using TEa derived from biological variation as limit for the 
non-linear error (Table 4), samples were considered to have an acceptable non-
linear error up to 28 ng/mL on the standard curve. Hence, it is recommended 
that concentrations of feline IGF-I are determined below 28 ng/mL on the 
standard curve when using this assay.  
As presented in Paper II, there was a wide range of IGF-I concentrations in 
healthy cats (range 86–1216 ng/mL). Three acromegalic cats had higher IGF-I 
concentrations (2029, 2869, and 3849 ng/mL) than healthy cats. Unfortunately 
no serum from cats with pituitary dwarfism was available. 
Over six days of storage at 20°C, IGF-I varied between -3.6 and 10.4% and 
at 2-4°C  between -1.7 and 6% (IV). If kept at 2-4°C, the change of results 
after 14 days was between -8.9 and 6.2%.  
IGF-I immunoreactivity and recombinant human IGF-I eluted in the same 
fractions. IGF-I was detected in fractions 14-22 with a peak in fractions 18-20. 
When immunoreactivity was compared in serum before and after size- 
exclusion chromatography the O/E ratio was between 98.2 and 115.2%. On 
WLB IGFBPs in fractions from size-exclusion chromatography were detected 
before IGF-I eluted from the column (Figure 2).  
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Figure 2. Western ligand blot of IGFBPs in fractions from size-exclusion chromatography of 
serum separated under acidic conditions. Samples were lyophilized and run on SDS-PAGE under 
non-reducing (A) and reducing (B) conditions. Immunoreactive IGF-I eluted from fraction 14 
with peak at fraction 18-20. Arrows indicate the molecular weight markers (M). 
6.3 Biological variation of insulin and IGF-I 
Biological variation of insulin and IGF-I in healthy cats is presented in Table 3. 
In addition, a cat with acromegaly was sampled and CVI was 8.1% for IGF-I 
(II). 
 
Table 3. Biological variation of insulin and IGF-I in healthy cats. Between cat coefficient of 
variation (CVG), within cat coefficient of variation (CVI), analytical coefficient of variation 
(CVA), sample occasion (Socc). 
  Balanced ANOVA Unbalanced ANOVA 
Insulin CVG CVI CVA CVG CVI CVA 
1     46.3 39.7 5.3 
2  44.3 42.9 5.5    
IGF-I        
3     65.7 8.2 1.8 
4  64.1 7.4 1.5    
5  63.9 7.8 1.7    
1= Socc A deleted in two cats, cats n=7, Socc n=4-5 
2= all Socc A deleted, cats n=7, Socc n=4 
3= Socc C excluded in one cat, cats n=7, Socc n=4-5 
4= All Socc C excluded, cats n=7, Socc n=4 
5= One cat excluded, cats n=6, Socc n=5 
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Based on recommendations (Fraser, 2001) desirable CVA should be less 
than 0.5CVI. For insulin CVI varied between 39.7 and 42.9% which makes 
desirable CVA for insulin assays in cats to be below 19.9-21.5%. Total CVA for 
the feline insulin ELISA presented in Paper I was 10.1-19.4% and thus the 
assay met the desirable performance. For IGF-I CVI varied between 7.4 and 
8.2% and hence desirable limits for CVA was 3.7-4.1%. Total CVA for the IGF-
I ELISA exceeded the limit of 4.1% by 0.2-2.3%.  
As presented in Table 4, CVA at low and high concentrations had little 
effect on INDI and RCV. Index of individuality for IGF-I indicated marked 
individuality (defined as <0.6) and hence use of population based RI may be of 
limited use. For insulin INDI was in a grey zone (0.6-1.4) indicating that 
population based RI may be used but with caution (Walton, 2012). Total error 
allowable for IGF-I and insulin was 23.4 and 47.8%, respectively. 
Table 4. Index of individuality (INDI), Total error allowable (TEa) and reference change value 
(RCV) based on data from biological variation derived from unbalanced ANOVA. Total 
analytical CV (CVA) from assay validations were used: CVA IGF-I low and high concentration 
(6.4 and 5.8%), CVA insulin low and high concentrations (16.9 and 11.4%). 
 IGF-I Insulin 
INDI low 0.16 0.93 
INDI high 0.15 0.89 
TEa 23.4 47.8 
RCV low  28.8 119.6 
RCV high  27.8 114.5 
 
 
6.4 IGF-I concentrations in health and diabetes 
The wide range of IGF-I concentrations in healthy cats (II) was investigated by 
determining factors associated with IGF-I concentrations. Weight and IGF-I 
were strongly positively associated in healthy cats (II, p<0.000001) and in cats 
with newly diagnosed DM (III, p=0.002). In cats with DM insulin was also 
positively associated with IGF-I concentrations (III, p=0.002). Age and gender 
were not significant (II, III). There were no significant interactions between 
any of the significant variables in the prediction of IGF-I. In Manuscript IV the 
effect of insulin treatment was determined in a longitudinal study design. In 
these cats weight and fructosamine were negatively correlated, which resulted 
in collinearity and, based on Akaike Information Criteria and p-values, it was 
decided to exclude weight from the final statistical model. In the final model 
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insulin was positively associated with IGF-I and fructosamine negatively 
associated with IGF-I (p=0.005 and p<0.0001, respectively). The positive 
relationship between insulin and IGF-I (Manuscript IV) was seen up to insulin 
concentrations of 60 ng/L, but not at higher concentrations. This concentration-
dependent association was also seen in Manuscript III where the association 
between IGF-I and insulin did not reach significance in healthy animals with 
higher insulin concentrations (p=0.09). In the final model presented in 
Manuscript IV age did not reach statistical significance but improved the 
model fit and was kept in the final model. Results from Paper II and 
Manuscript III indicate that in healthy cats 1 kg increase in weight is associated 
with an increase of IGF-I of approximately 40% (II, III). In diabetic cats, 
sampled before initiation of insulin treatment, doubling of insulin 
concentration is associated by an increase of IGF-I by 30% (Manuscript III) 
and in diabetic cats under treatment, at concentrations up to 60 ng/L doubling 
of insulin concentration was associated with an increase of IGF-I by 95 ng/mL 
(Manuscript IV).  
6.5 Circulating IGF-binding forms 
To further investigate the wide IGF-I concentrations in cats (Paper II and 
Manuscript III) the distribution of endogenous IGF-binding forms was studied 
by size-exclusion chromatography under neutral conditions (Manuscript III, 
IV). Two major peaks representing the ternary complex (150kDa) and binary 
complexes (30-50kDa) were present. Peaks of similar molecular masses have 
been identified previously in cats, humans and rodents using the same 
methodology (Renes et al., 2014; van Duyvenvoorde et al., 2008; Lewitt et al., 
2001; Lewitt et al., 2000). In Manuscript III and IV IGF-binding profiles were 
visualized by incubating serum with tracer amounts of h-125I-IGF-II to 
equilibrium. The data is presented by generating three equal IGF-I intervals 
derived from the RI presented in Paper II (IGF-I ? 462 ng/mL, 463-833 ng/mL 
and ? 834 ng/mL). Figure 3 presents one healthy and one diabetic cat 
representative of each interval. Over the range of IGF-I concentrations, more 
relative binding of h-125I-IGF-II into the 150kDa complex was associated with 
increasing IGF-I concentrations. When performing univariate linear regression 
analyses on diabetic and healthy cats altogether (III), results indicated a 
significant association between ln-150kDa/30-50kDa-ratio and ln-IGF-I 
concentrations (p<0.0001) and ln-150kDa/30-50kDa-ratio and ln-insulin 
(p=0.006).  
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Figure 3. IGF-binding profiles after size separation in healthy and diabetic (DM) cats before 
insulin treatment after incubation with human 125I-IGF-II and radioactivity (C.P.M., counts per 
minute) detected by gammacounting. Each graph shows a representative cat. IGF-I concentrations 
were analyzed with an IGF-I ELISA. The acromegalic cats were on insulin treatment. 
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Figure 4. Size separation under neutral conditions using a Superose 12 column. Serum was either 
incubated with human 125I-IGF-II before separation and counts per minute (C.P.M) counted in 
each fraction, or serum was run over the column and IGF-I immunoreactivity in the fractions 
measured by an IGF-I ELISA. The asterisk (*) indicates that the IGF-I concentration was above 
the highest standard point (50 ng/mL).  
 
In Manuscript III, three samples were size-separated without tracer and 
fractions analysed with the IGF-I ELISA. IGF-I immunoreactivity was mainly 
seen in the 150kDa complex regardless of the size of 30-50kDa complex. A 
representative cat is presented in Figure 4. 
In Manuscript IV, IGF-binding forms were studied using tracer 
methodology in seven cats at diagnosis (T0) of DM and 2-4 weeks after 
initiating insulin treatment (T1). As shown in Figure 5, in three cats that went 
into remission the 150/30-50kDa ratio increased (p=0.03) along with IGF-I, 
whereas no change in the 150kDa/30-50kDa ratio was seen in four cats that 
had poor glycaemic control and did not go into remission (p=0.7, n=4). 
IGFBP-3 also increased between T0 and T1 in cats that went into remission 
(p=0.03) but IGFBP-5 and IGF-II did not show any obvious patterns. IGF-II 
concentrations were higher than IGF-I concentrations.  Samples in which IGF-I 
concentrations were measured by both MS and ELISA (n=6) yielded higher 
concentrations when analysed with MS.  
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Figure 5. Distribution of IGF-binding forms after incubation with 125I-IGF-II in diabetic cats 
achieving remission (n=3; A,B) or not (n=4; C,D). Cats were sampled at diagnosis (A, C) and 2-4 
weeks after insulin treatment (B,D). Results are expressed as counts per minute (C.P.M., mean ± 
SEM). 
6.6 Predictors of remisson of diabetes mellitus 
Using a longitudinal study design (IV) diabetic cats were sampled up to one 
year after the commencement of insulin treatment. There was a significant 
increase in IGF-I concentrations between T0 (baseline) and T1 (2-4 weeks, 
p=0.0001) but no significant changes at later time-points. Seven cats went into 
remission during the study period, all within 5 months from T0. At T1, there 
were 22 diabetic cats still in the study and of these six went into remission. The 
cats achieving remission were all treated by the same veterinary practitioner 
and all of these owners used home glucose monitoring. The effect of 
“veterinary practitioner” was not significant (data not included). In predicting 
remission, IGF-I was significant at p=0.046 and glucose, fructosamine and 
insulin were not (p=0.11, p=0.24 and 0.31, respectively). The estimated AUC 
for IGF-I in the ROC analysis was 0.80 (CI 0.62-0.99), for glucose 0.76 (CI 
0.54-0.97), fructosamine 0.65 (CI 0.39-0.90) and for insulin 0.61 (CI 0.33-
0.90). 
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7 Discussion 
This thesis highlights the importance of validating IGF-I assays with special 
focus on potential interference by IGFBPs. Commercial assays for IGF-I and 
insulin were validated for feline samples. To set objective limits for assay 
performance, and aid in interpretation of repeated sampling in clinical settings, 
biological variation for IGF-I and insulin were determined, to my knowledge, 
for the first time in cats. In the feline insulin ELISA there was a statistically 
significant effect of sample position on the plate, however in the light of 
biological variation, assay variation was within the desirable limits. In the IGF-
I assay the interference of IGFBPs was overcome by the addition of IGF-II in 
greater quantities than recommended for human serum. 
In the studies presented in this thesis a number of factors were evaluated for 
their relationship to serum IGF-I concentrations. This is important for 
interpretation and understanding of the clinical value of IGF-I measurements. 
Weight, for example, was strongly associated with IGF-I concentrations in 
healthy and diabetic cats.  
Since IGF-I is almost exclusively used in diabetic cats when screening for 
acromegaly it was considered important to study the IGF system in diabetic 
cats. It has been suggested that pancreatic beta cell function is important for 
IGF-I concentrations in diabetic cats and for the first time an association 
between serum insulin and IGF-I is demonstrated in newly-diagnosed diabetic 
cats. Because many insulin treated diabetic cats can achieve remission there is 
interest in developing prognostic markers. In this thesis IGF-I emerges as a 
promising prognostic marker of remission of feline DM.  
There follows a discussion for each of the most important findings in this 
thesis. Please refer to Paper and Manuscript I-IV for detailed discussion of 
each paper.  
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7.1 Position effects in ELISA validation  
Paper I reported significant effect of sample positioning on ELISA plates and 
recommended that this should be investigated when performing validation 
studies. Finding of position effects on ELISA plates have been reported 
previously (Miller et al., 2009; Shekarchi et al., 1984), however to my 
knowledge this is not often taken into account when validating assays. 
For the feline insulin ELISA, the mechanism behind this effect was not 
elucidated. The position effect was of the same magnitude as between plate 
variation and hence should be taken into account when identifying sources of 
assay variation. 
ISO recommends all sources of variation be taken into account, however the 
application of these guidelines may be found tedious and laborious by 
laboratories (Rozet et al., 2011). One feasible way to evaluate position effect is 
to incorporate it into the study design for precision. It has been recommended 
that precision studies should be performed by analysing samples with different 
concentrations in 3-5 replicates on 5 days (CLSI, 2014; CLSI, 2005). Instead I 
would recommend analysing samples with different concentrations in 6 
replicates, with 3 duplicates pipetted to fixed positions on the ELISA plate on 
several days. 
The best allocation of samples on an ELISA plate would be to randomly 
distribute all replicates, including standards. However, this would be 
cumbersome with 96 wells and a time limit. Manufacturers of ELISA often 
recommend to analyse 1-3 controls with different concentrations but no 
recommendations are usually made on how the controls should be situated on 
the plate. Depending on whether there is a significant effect of rows or 
columns it could be a valuable procedure to pipette the same controls in both 
the first and last columns or rows.  
7.2 Measurements of feline insulin and biological variation 
Feline insulin differs four amino acids from human insulin (Hallden et al., 
1986) and previous studies have shown that not all insulin assays intended for 
human use are suitable for feline samples (Lutz & Rand, 1993). The precision 
of the feline insulin ELISA validated in Paper I met the desirable specifications 
based on biological variation at all concentrations, it detected a biological 
response and had acceptable O/E ratio after dilution. Hence it is concluded that 
this assay can be used for measuring feline insulin. 
Evaluation of stability, consistency upon dilution and spiking studies for 
insulin in Paper I were performed by calculating critical limits. During analysis 
of insulin stability in Paper I it was apparent that the concentrations declined 
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systematically even before the critical limit was exceeded. The critical limit is 
purely based on statistical calculations and does not imply whether the assay is 
clinically useful or not. In clinical practice insulin is not used as a diagnostic 
tool and the clinical importance of a decline of this magnitude has not been 
evaluated. 
The critical limits were also used in Paper I to evaluate consistency upon 
dilution. The critical limits for O/E ratio given in percent were in the 
magnitude of ±46-66% which is considered a clinically unacceptable 
consistency for insulin assays in humans where ±15% has been recommended 
(Robbins et al., 1996). However, the O/E ratios were between 80 and 105% 
which was close to the recommended limits for human insulin assays. 
Previous studies have found lower insulin concentrations at diagnosis in the 
majority of cats with DM compared to healthy cats (Tschuor et al., 2011; Kirk 
et al., 1993) and the results of study I support those findings. It has been 
suggested that fasting insulin can be used for evaluating insulin sensitivity in 
healthy cats (Appleton et al., 2005), and by detecting abnormal results cats 
with impaired insulin sensitivity and risk of developing diabetes may be 
identified, and preventive actions can be taken. The wide range of insulin 
concentrations in healthy cats can make interpretation difficult and more 
healthy cats need to be sampled to determine reference intervals. The results of 
biological variation of insulin indicated that care should be taken when 
evaluating results with respect to population based RI and RCV may be a better 
approach. 
Depending on statistical analysis CVI for insulin varied between 40 and 
43%. In one study CVI of fasting serum insulin in normal people was 24.2% 
(Borai et al., 2013), however, as glucose tolerance declined CVI increased to 
28.1-33.3%. The cats in study I were not evaluated for impaired insulin 
sensitivity and it is possible this could have affected the results. In one study of 
cats sampled twice, CVI of insulin was 23% (Appleton et al., 2001). However, 
in contrast to that study where cats were sampled by central venous catheters, 
the cats in this study were sampled from the cephalic vein. This may affect 
results since sampling techniques can influence stress at sampling. The stress 
induced hyperglycemia seen in cats is accompanied by increased insulin 
concentrations (Rand et al., 2002) and may be a contributing reason for the 
high CVI and CVG reported in Section 6.3. Even though the cats sampled for 
biological variation did not appear stressed at sampling, some cats are 
immobilized by fright and the magnitude of stress may be difficult to assess. 
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7.3 Measurements of feline IGF-I and biological variation 
For the IGF-I ELISA the same sample pipetted in all wells did not show any 
significant position effect and hence this was not further evaluated. However 
the sample used for the position effect was one high control sample supplied 
with the ELISA-kit, based on human serum, and it is possible there would have 
been another result if feline serum had been used.  
Feline serum samples measured by the IGF-I ELISA were non-linear 
according to CLSI. It is difficult to establish clinically acceptable limits for 
non-linear errors of IGF-I in cats. However, by determining the biological 
variation and hence TEa of IGF-I, the guidelines from Westgard were used to 
calculate the acceptable non-linear error. The non-linear error did not exceed 
TEa up to 28 ng/mL on the standard curve and hence values determined below 
this point were considered acceptable.  
The finding of non-linearity above 28 ng/mL in the IGF-I ELISA was likely 
due to interference of IGFBPs which was seen at high IGF-I concentrations. 
When results were determined at the upper end of the standard curve, the 
amount of IGF-II added to prevent interference was not enough. In most 
species GH stimulates synthesis of IGF-I and ALS and, by ternary complex 
formation, IGFBP-3, the most abundant IGFBP. Thus high IGF-I 
concentrations may be accompanied by high IGFBP-3 concentrations. The 
affinity of feline IGFBPs for human IGF-II has not been studied and it is for 
example possible that an increase of any feline IGFBP with low affinity for 
human IGF-II could influence the results. In humans there is a consensus on 
how to perform method validation for analysis of IGF-I (Clemmons, 2011) and 
it seems reasonable that this consensus is followed in cats until evidence 
suggest otherwise. For example we have no studies on which diseases that may 
increase IGFBPs in cats and thus no indications of what sera to preferably 
include in method validations. One study compared different IGF-I assays in 
cats and IGF-I concentrations varied in both healthy and diseased cats 
depending on which assay was used (Tschuor et al., 2012). In that study no 
comparison was made with serum subjected to size-exclusion chromatography 
for removal of IGFBPs and it is not known if discrepancies were due to 
IGFBPs. Nevertheless, since serum concentrations of the six IGFBPs may 
differ between healthy and diseased cats it is important to not only include sera 
from healthy animals in validation studies. 
Even if there was interference of IGFBPs in the assay it seemed that the 
assay could correctly identify acromegaly. However, few acromegalic cats 
were used in this validation study and the diagnostic performance of the assay 
needs to be evaluated in a larger population. Unfortunately no cats with 
pituitary GH-deficiency were available, however it is clear that one should be 
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cautious if using the IGF-I ELISA for diagnosing this disease since interfering 
IGFBPs will cause false low concentrations. 
Biological variation of IGF-I in cats was investigated in Paper II and has 
not been reported before. In humans CVI of IGF-I is reported to be 9-21% 
when results were obtained using ANOVA (Ankrah-Tetteh et al., 2008; 
Nguyen et al., 2008). In cats CVI of IGF-I was calculated to 7.4-8.2% in 
healthy cats and in one cat with acromegaly, which was similar to, or slightly 
less than in healthy people.  
When measuring IGF-I in healthy adult cats there was a wide RI and INDI 
indicated that RI should be stratified. To identify possible factors for 
stratification of RI, study II, III and IV aimed at identifying factors associated 
with IGF-I concentrations. 
7.4 Predictors of IGF-I concentrations 
7.4.1 General characteristics and markers of glycaemic control 
In study II and III a strong association between weight and IGF-I 
concentrations was seen in both healthy and diabetic cats and it is proposed 
that weight should be taken into account when interpreting IGF-I 
concentrations in cats. This finding contrasts to IGF-I in humans where the 
reference interval for IGF-I often is stratified on gender and age (Brabant & 
Wallaschofski, 2007). The association between weight and IGF-I has been 
presented previously (Berg et al., 2007; Maxwell et al., 1999) whereas another 
study did not see this relationship (Reusch et al., 2006). It is not clear whether 
the association between IGF-I and weight is due to size or body composition. 
In dogs the same association between weight and IGF-I has been demonstrated. 
A genetic variation in the IGF1 gene has been found between breeds of 
different body sizes (Sutter et al., 2007). However, IGF-I is not only dependent 
on size but also on body composition in dogs. IGF-I increased in Beagle dogs 
that were overfed (Gayet et al., 2004). Similar studies have not been done in 
the cat and the effect of body size versus body composition on IGF-I 
concentrations is currently not known. In study IV body composition measured 
as body condition score was not significantly associated with IGF-I and in 
study II and III this differentiation was not made. 
In healthy cats neither age nor sex was significantly associated with IGF-I. 
Most cats in study I-IV were castrated which could be one explanation for the 
lack of association with sex; and another study presented similar results 
(Reusch et al., 2006). Age was not a significant predictor of IGF-I (II, III) 
however in the longitudinal study (IV) age improved the model fit and was 
near the set ?-threshold (p=0.052). In this study (IV) the association between 
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age and IGF-I was positive whereas another study presented a negative 
relationship (Reusch et al., 2006). Any reason for the contradictory results is 
not known but may be due to confounders not included in the model. 
In newly diagnosed diabetic cats sampled before insulin treatment (III) 
insulin, in addition to weight, was associated with IGF-I. There were no 
significant interactions between weight and insulin and this indicate that 
insulin concentrations did not modify the effect of weight on IGF-I 
concentrations. In diabetic cats (IV) the independent association between IGF-I 
and insulin was present up to 60 ng/L but not at higher concentrations. An 
association between beta cell capacity and IGF-I has been demonstrated in type 
1 DM in people (Sorensen et al., 2015; Hedman et al., 2004) and it has been 
proposed that increased beta cell function in cats during insulin treatment is a 
cause of increased IGF-I concentrations (Alt et al., 2007; Reusch et al., 2006). 
However, no one has previously presented evidence that demonstrates this 
relationship in cats. One contributing factor suggested for this association is 
that expression of hepatic GH-receptors are stimulated by insulin (Leung et al., 
2000; Baxter et al., 1980). 
Results of the longitudinal study of diabetic cats (IV) indicated that 
fructosamine and weight were negatively associated which resulted in 
collinearity. It is not surprising that high fructosamine concentrations, 
associated with poor glycaemic control, are associated with a malnourished 
state in diabetic animals. Based on Aikake Information Criteria and p-values it 
was decided to exclude weight from the final model. Based on the findings in 
study II, III and IV it can be concluded that weight is an important predictor of 
IGF-I concentrations in healthy and diabetic cats but glycaemic control must 
also be taken into account when interpreting IGF-I concentrations in diabetic 
animals. In these studies the use of IGF-I as a screening marker for acromegaly 
was not investigated. However, as a result of the present studies we now have a 
better understanding of feline IGF physiology and further studies addressing 
the clinical value of IGF-I measurements in a range of clinical conditions 
including acromegaly, will be possible. 
7.4.2 Molecular distribution of IGF-binding forms in serum 
Since the 150kDa ternary complex stabilises IGF-I, prolongs its half-life and 
therefore affect serum concentrations, Manuscript III and IV investigated the 
molecular distribution of IGFs in the circulation of healthy and diabetic cats. 
Results of study III indicate that less relative binding of h-125I-IGF-II in the 
150kDa complex, is associated with lower IGF-I concentrations and this 
pattern is seen in both healthy and diabetic cats. In a previous study less 
binding in the 150kDa complex was only seen in healthy cats (Lewitt et al., 
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2000). This discrepancy could be explained by the fact that cats sampled for 
study III represented a range of IGF-I concentrations whereas this was not the 
case in the study by Lewitt et al (2000).  
The results of Manuscript III, together with the previous study published by 
Lewitt et al (2000), indicate that in both healthy and diabetic cats ALS is not in 
excess across the range of IGF-I concentrations, but may be at high 
concentrations. Low IGF-I concentrations are associated with low ternary 
complex formation and relatively increased 30-50kDa complexes. It is most 
likely that ALS is the limiting factor for 150kDa complex formation in cats 
since it was possible to shift the 30-50kDa peak by adding human serum which 
is known to contain excess ALS, as well as from cats which were hypothesized 
to have high ALS (Lewitt et al., 2000). Previous results found no differences in 
IGFBP-3 visualized on WLB between cats with low and high amount of 
150kDa complex (Lewitt et al., 2000), which makes the alternative hypothesis 
that IGFBP-3 is the limiting factor for ternary complex formation less likely. 
GH is a major stimulant of hepatic ALS synthesis and one can speculate on 
the role of GH in determining the patterns observed. GH also stimulates 
production of IGF-I and IGFBP-3 concentrations, since circulating IGFBP-3 
levels depend on ternary complex formation (Olivecrona et al., 1999). In 
human GH deficiency all three components of the ternary complex are reduced 
(Domene et al., 2011). GH and IGF-I have been shown to stimulate adipocyte 
differentiation (Smith et al., 1988; Kuri-Harcuch & Green, 1978) and, since cat 
serum has been observed to be relatively deficient in a factor that stimulates 
adipocyte differentiation (Kuri-Harcuch & Green, 1978) it is possible that 
some cat serum is IGF- or GH-deficient. In the absence of an available 
validated feline GH assay and no reference material, it is difficult to compare 
GH concentrations in serum between species. 
In Manuscript IV there was a noticeable increase in IGF-I concentrations 
between T0 and T1. In cats which later went into remission the relative amount 
of h-125I-IGF-II binding into the 150Da complex increased but this was not 
seen in cats which did not achieve remission. In addition, in three cats that 
went into remission IGFBP-3 concentrations were measured by MS and were 
found to be increased. The increase of IGF-I and IGFBP-3 concentrations in 
cats which went into remission is likely to reflect an increased amount of 
ternary complex.  
In Manuscript IV, IGF-I was measured both by MS and ELISA in six 
samples. This was done in order to compare concentrations of IGF-I with IGF-
II, IGFBP-3 and IGFBP-5 when using the same methodology. As in humans it 
seemed that IGF-II is higher than IGF-I (Rajaram et al., 1997). In all six 
samples IGF-I concentrations were higher when analysed with MS compared 
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to ELISA. Higher concentrations of IGF-I measured by MS compared to 
immunoassay has been demonstrated when analysing human serum (Kay et al., 
2013). 
It has been proposed that insulin may have an effect on ALS concentrations 
and this contributes to ALS regulation under nutritional deprivation (Dai & 
Baxter, 1994; Dai et al., 1994). Decreased ALS concentrations that increase 
during insulin treatment have been seen in both diabetic humans and rats 
(Bereket et al., 1996; Dai & Baxter, 1994). In Manuscript III a positive 
association was found between insulin concentration and relative amount of 
150kDa complex, and in Manuscript IV the relative amount of 150kDa 
complex increased after treatment with insulin, supporting an association 
between nutrition and the amount of ternary complex formed.  
IGF-I immunoreactivity was mainly found in the 150kDa complex 
regardless of the size of the 30-50kDa peak and this finding has also been 
observed in children (Renes et al., 2014). It is therefore likely that the 30-
50kDa complex represents binary complexes with IGF-II. However, the 
affinities of IGFs and IGFBPs in the cat are unknown and it cannot be 
excluded that results would have been different if feline IGFs were available 
and used as tracer. Further studies of affinities and physiology are needed to 
understand the IGF system in cats. 
7.5 Predictors of remisson of feline diabetes mellitus 
It is considered that early treatment and near euglycaemic control are key 
factors in achieving remission of DM in cats (Gottlieb & Rand, 2013). In study 
III and IV IGF-I concentrations were associated with markers of glycaemic 
control and preliminary evidence indicates that IGF-I concentrations at 2-4 
weeks after initiating insulin treatment (T1) predict remission (IV). The finding 
of increased serum IGF-I concentrations after initiation of insulin treatment has 
been reported previously (Alt et al., 2007; Reusch et al., 2006). Interestingly, 
in cats, one study proposed a protective effect of IGF-I on feline beta cells 
during hyperglycaemia (Link et al., 2013). IGF-I may also itself, by enhancing 
insulin action (Clemmons, 2012), contribute directly to glycaemic control and  
therefore remission. 
 Since glycaemic control is associated with remission, endogenous insulin, 
fructosamine and glucose concentrations were investigated as predictive 
markers, in addition to IGF-I. These had lower AUCs than IGF-I and were not 
statistically significant (IV). Previous studies which investigated serum insulin 
concentrations at diagnosis as a possible predictor for remission, found that 
insulin concentrations in diabetic cats were lower than in healthy cats and did 
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not predict remission (Tschuor et al., 2011; Nelson et al., 1999). It has been 
proposed that reduction of beta cell function is transient and due to 
glucotoxicity. When the animal is treated with insulin and glucotoxicity is 
reversed, the insulin-secreting capacity is restored (Zini et al., 2009; Nelson et 
al., 1999). Interestingly, hyperlipidemia does not seem to cause decreased beta 
cell function in cats (Zini et al., 2009). In study IV fasting insulin was 
measured 2-4 weeks after initiating insulin treatment and there was no 
difference between cats going into remission or not. 
Glucose was not a predictor of remission. Cats are prone to stress-induced 
hyperglycaemia which may contribute to larger variation and thus affect 
results. Fructosamine is a glycated protein and is considered to reflect 
glycaemic control during the last 1-2 weeks (Crenshaw et al., 1996). It is 
possible that IGF-I is reflecting the glycaemic and nutritional status in a shorter 
time frame and results would have been different if data from later sampling 
occasions were used. However, at later sampling occasions there were fewer 
animals left in the study which resulted in less power. For the clinician and 
owners a marker for remission early in the course of the disease is preferable.  
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8 Conclusions 
? In validating two ELISAs (IGF-I and insulin) for use in feline 
medicine it was concluded that laboratories, in validating their assays, 
should be aware of position effects on assay plates and, for IGF-I 
assays, interference by circulating IGF-binding proteins.  
 
? Biological variation should be taken into account when recommending 
limits for assay performance and in interpreting clinical results after 
repeated sampling. For IGF-I, between animal variation was high 
(~65%) while within animal variation was considerable lower (~8%).  
 
? There is a wide range of IGF-I concentrations in healthy and diabetic 
cats that is in part determined by weight. Weight should be used to 
stratify reference intervals for feline IGF-I.  
 
? IGF-I concentrations are related to the amount of the IGFBP-3 
150kDa ternary complex formation in healthy and diabetic cats. 
 
? Glycaemic control should be taken into consideration when 
interpreting IGF-I concentrations in diabetic cats. 
 
? IGF-I response to insulin treatment shows promise as a predictive 
marker for remission in feline diabetes mellitus. 
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9 Populärvetenskaplig sammanfattning 
Inom veterinärmedicinen används analys av insulin-liknande tillväxtfaktor-I 
(IGF-I) framförallt vid diagnos av sjukdomar relaterade till tillväxthormon. 
Den vanligaste indikationen för mätning av IGF-I hos katt är vid diagnos av 
akromegali vilket orsakas av en tumör i hypofysen som producerar 
tillväxthormon. Tillväxthormon ger insulinresistens och akromegali ses nästan 
uteslutande hos katter med svårbehandlad diabetes mellitus (DM). Katten är en 
strikt köttätare och det finns indikationer på att regleringen av IGF-systemet 
skiljer sig från andra djurslag. För att korrekt tolka provsvar för IGF-I hos katt 
är det viktigt att förstå fysiologin samt identifiera faktorer som påverkar 
koncentrationerna och som bör tas i beaktande vid tolkning. De flesta katter 
med DM har en typ som liknar människans typ 2, men till skillnad från 
människor har katter ofta låga nivåer av insulin vid diagnos. Trots detta kan de 
flesta katter tillfriskna från sin diabetes (remission) om rätt behandling sätts in. 
Snabbt insatt insulinbehandling och kontroll över blodsockernivån anses vara 
den viktigaste faktorn för tillfrisknande av DM hos katt men hittills har ingen 
blodmarkör identifierats som kan användas för att förutsäga chansen att katten 
går i remission. 
Det övergripande målet med denna avhandling var att studera IGF-I hos 
friska katter och katter med DM för att identifiera faktorer som bör tas i 
beaktande vid tolkning av provsvar. Ytterligare ett mål var att undersöka om 
IGF-I och insulin kan användas för att förutsäga vilka katter som kan tillfriskna 
från sin diabetes. 
En kommersiell analysmetod (ELISA) för IGF-I respektive insulin 
utvärderades för analys av blodprov från katt och bägge metoderna fungerade 
bra. För insulin sågs en signifikant effekt på resultaten beroende var proven 
analyserades på ELISA-plattan men den totala variationen överskred inte 
uppsatta gränser. En slutsats i denna avhandling är att positionseffekter bör 
undersökas vid validering av ELISA. För IGF-I ELISA störde IGF-bindande 
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proteiner analysen vid höga koncentrationer av IGF-I men detta kunde hanteras 
genom att späda prover mer än vad som rekommenderats för prover från 
människa. Det var en stor spännvidd av IGF-I koncentrationer hos både friska 
katter och katter med DM. Vikt hade ett starkt positivt samband med IGF-I hos 
friska katter men ingen koppling sågs till ålder och kön. Hos katter med DM 
provtagna före insulinbehandling hade både vikt och insulinkoncentrationer ett 
positivt samband med IGF-I. Hos katter med DM provtagna under behandling 
hade markörer för blodsockerkontroll (insulin och fruktosamin) ett samband 
med IGF-I koncentrationer.  
Huvuddelen av IGF-I cirkulerar bundet till sex olika bindarproteiner och 
distributionen av dessa komplex skiljde sig åt från vad som rapporterats hos 
friska vuxna människor. Detta tyder på att katten kan ha en annan reglering av 
IGF-systemet än människa och man skall vara försiktig med att extrapolera vad 
som är känt från människa till katt. 
Hos katter under insulinbehandling sågs en tydlig ökning av IGF-I från 
diagnos till efter 2-4 veckors insulinbehandling. Katter som senare 
tillfrisknande från sin diabetes hade högre koncentrationer 2-4 veckor efter 
insatt insulinbehandling än de som inte tillfrisknande.  
Sammanfattningsvis har jag i denna avhandling visat att man vid tolkning 
av IGF-I hos katt bör ta hänsyn till vikt. Stora katter har normalt högre 
koncentrationer än små katter. Referensvärden bör tas fram med hänsyn till 
vikt och inte kön och ålder som för människor. Hos katter med diabetes bör 
blodsockerkontrollen tas i beaktande vid tolkning av provsvar då dålig kontroll 
av blodsockret kan ge lägre värden av IGF-I. Koncentrationen av IGF-I efter 
insatt insulinbehandling kan vara en möjlig markör för chansen att tillfriskna 
från DM.  
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